GGrantIndex
Sort

82,697 grants matching vaccine development

Antibody immunotherapeutics for biodefense against Lassa virus

$1,238,702
Robert F Garry · Tulane University Of Louisiana · R01 · FY2016 · AI

Medical Scientist Training Program

$1,238,676
Christopher S. Williams · Vanderbilt University · T32 · FY2017 · GM

Studies on Arthropod Vectors of Disease

$1,238,602
Robert Gwadz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI

DNA Vaccine for Seasonal & Pandemic Influenza

$1,238,541
Deborah L. Fuller · Albany Medical College · U01 · FY2009 · AI

Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning

$1,238,429
Konstantin Ichtchenko · New York University School Of Medicine · R01 · FY2012 · AI

Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning

$1,238,429
Konstantin Ichtchenko · New York University School Of Medicine · R01 · FY2016 · AI

Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning

$1,238,429
Konstantin Ichtchenko · New York University School Of Medicine · R01 · FY2015 · AI

Structure-Function Studies of the HIV-1 Envelope Glycoproteins

$1,238,374
Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

CTL and HIV Polymorphisms in Heterosexual Transmission

$1,238,320
Eric Hunter · Emory University · R01 · FY2008 · AI

Diagnosing and predicting risk in children with SARS-CoV-2- related illness

$1,238,182
Jane C Burns · University Of California, San Diego · R33 · FY2023 · HD

Monoclonal Antibodies in Biodefense: Ebola Viruses

$1,238,148
Larry Zeitlin · Mapp Biopharmaceutical, Inc. · U01 · FY2007 · AI

Laboratory Support

$1,238,055
Wendy Stevens · Wits Health Consortium (Pty), Ltd · U19 · FY2007 · AI

CD40L-Adjuvanted Vaccines for HIV/AIDS

$1,237,954
Rama Rao Amara · Emory University · P01 · FY2011 · AI

Novel Strategies for Brain Tumor Therapy

$1,237,376
Ian F. Pollack · University Of Pittsburgh At Pittsburgh · P01 · FY2012 · NS

Immunobiology, molecular virology and countermeasures of highly pathogenic viruses

$1,236,847
Andrea Marzi · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Colorado AIDS Clinical Trials Unit

$1,236,675
Thomas B. Campbell · University Of Colorado Denver · U01 · FY2007 · AI

DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES

$1,236,651
Emily Voigt · Access To Advanced Health Institute · N01 · FY2023 · AI

The effect of peptide therapy and allergen provocation on Fel d1-specific T Cells

$1,236,590
Mark Larche · Mcmaster University · U19 · FY2016 · AI

Sirtuin -Dependent Regulation of Tuberculosis and HIV Interactions in Macrophages

$1,236,573
Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2025 · AI

CONTROLLED RELEASE POLYMERS FOR BRAIN TUMORS (U19 CA 528

$1,236,519
Johns Hopkins University · U19 · FY2002 · CA

Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit

$1,236,361
Margaret A Fischl · University Of Miami School Of Medicine · U01 · FY2007 · AI

San Antonio STI TM CRC

$1,236,129
University Of Texas Hlth Sci Ctr San Ant · U19 · FY2004 · AI

Surgery Branch Cell Prep Core

$1,236,025
John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA

Cell Production Core Facility

$1,236,025
Robert Somerville · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA

Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever

$1,235,927
Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2018 · AI